About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
CRESCENT BIOPHARMA, INC. (CBIO): Insider Trades and Fund Holdings
In the past 12 months, CRESCENT BIOPHARMA, INC. insiders reported 1 open-market purchase worth $12.4M and 16 sales worth $1.51M; 16 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144), Congress trades and fund moves in the past year, newest first.
- Sep 18, 2026Insider saleCEO Joshua T. Brumm sold $130,956 under a 10b5-1 plan
- Sep 18, 2026Insider saleCOO Jonathan McNeill sold $64,150 under a 10b5-1 plan
- Sep 17, 2026Planned saleJoshua T Brumm (officer, director) filed notice to sell about $154,843 around Sep 18, 2026
- Sep 17, 2026Planned saleJonathan McNeill (officer) filed notice to sell about $75,850 around Sep 18, 2026
- Sep 16, 2026Insider saleCEO Joshua T. Brumm sold $28,819 under a 10b5-1 plan
- Sep 16, 2026Insider saleCOO Jonathan McNeill sold $13,085 under a 10b5-1 plan
- Sep 16, 2026Insider saleChief Scientific Officer Jan Pinkas sold $11,778 under a 10b5-1 plan
- Sep 16, 2026Insider saleChief Medical Officer Ellie Eunkyung Im sold $11,152 under a 10b5-1 plan
- Sep 16, 2026Insider saleSee Remarks Barbara Harlin Bispham sold $11,098 under a 10b5-1 plan
- Sep 16, 2026Insider saleCFO Richard William Scalzo sold $10,167 under a 10b5-1 plan
- Sep 16, 2026Insider saleSee Remarks Ryan Lynch sold $4,296 under a 10b5-1 plan
- Sep 16, 2026Planned saleJoshua T Brumm (officer, director) filed notice to sell about $33,295 around Sep 16, 2026
- Sep 16, 2026Planned saleJonathan McNeill (officer) filed notice to sell about $15,115 around Sep 16, 2026
- Jul 30, 2026NewsCompany reported: Quarterly or annual results
- Jul 16, 2026Insider buyDirector Fairmount Funds Management LLC bought $12.4 million
- Jun 30, 2026FundRenaissance Technologies sold out in Q2 2026 (13F filed Aug 13, 2026)
- Jun 22, 2026Insider saleCEO Joshua T. Brumm sold $761,067 under a 10b5-1 plan
- Jun 22, 2026Insider saleCOO Jonathan McNeill sold $369,677 under a 10b5-1 plan
- Jun 22, 2026Insider saleChief Scientific Officer Jan Pinkas sold $23,171 under a 10b5-1 plan
- Jun 22, 2026Insider saleChief Medical Officer Ellie Eunkyung Im sold $21,930 under a 10b5-1 plan
- Jun 22, 2026Insider saleSee Remarks Barbara Harlin Bispham sold $21,912 under a 10b5-1 plan
- Jun 22, 2026Insider saleCFO Richard William Scalzo sold $20,005 under a 10b5-1 plan
- Jun 22, 2026Insider saleSee Remarks Ryan Lynch sold $8,365 under a 10b5-1 plan
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 18, 2026.
| Filed | Insider | Type | Value | Score |
|---|---|---|---|---|
| Sep 18 | Joshua T. BrummCEO | ▼ SELL10b5-1 | $131K | |
| Sep 18 | Jonathan McNeillCOO | ▼ SELL10b5-1 | $64K | |
| Sep 18 | Joshua T. BrummCEO | ▼ SELL10b5-1 | $29K | |
| Sep 18 | Jonathan McNeillCOO | ▼ SELL10b5-1 | $13K | |
| Sep 18 | Jan PinkasChief Scientific Officer | ▼ SELL10b5-1 | $12K | |
| Sep 18 | Ellie Eunkyung ImChief Medical Officer | ▼ SELL10b5-1 | $11K | |
| Sep 18 | Barbara Harlin BisphamSee Remarks | ▼ SELL10b5-1 | $11K | |
| Sep 18 | Richard William ScalzoCFO | ▼ SELL10b5-1 | $10K | |
| Sep 18 | Ryan LynchSee Remarks | ▼ SELL10b5-1 | $4K | |
| Jul 20 | Fairmount Funds Management LLCDirector | ▲ BUY | $12.4M | 49 |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Joshua T. Brumm | CEO | 0 | $0 | 3 | $921K |
| Jonathan McNeill | COO | 0 | $0 | 3 | $447K |
| Jan Pinkas | Chief Scientific Officer | 0 | $0 | 2 | $35K |
| Ellie Eunkyung Im | Chief Medical Officer | 0 | $0 | 2 | $33K |
| Barbara Harlin Bispham | See Remarks | 0 | $0 | 2 | $33K |
| Richard William Scalzo | CFO | 0 | $0 | 2 | $30K |
| Ryan Lynch | See Remarks | 0 | $0 | 2 | $13K |
| Fairmount Funds Management LLC | Director | 1 | $12.4M | 0 | $0 |
Buybacks and executive pay
| Year | CEO pay reported | CEO pay "actually paid" | Value of $100 invested |
|---|---|---|---|
| 2025 | $13.1M | $17.6M | n/a |
From the company's XBRL data filed with the SEC. "Actually paid" is the SEC's pay-versus-performance measure, which counts changes in the value of stock awards. "Value of $100 invested" is the company's cumulative shareholder return as reported, usually measured from five years earlier. See all buybacks and CEO pay across companies.
49 Fairmount Funds Management LLC (Director), 2026-07-16. What the score means
A All 17 insider trades reported on time. How it is graded
Tracked funds that report CBIO
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 0 | $0 | ▼ Sold out |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →